PMID- 36330446
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221105
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - The prevalence and genetic disorders spectrum of thalassemia among breast cancer 
      patients in Jiangxi province, China.
PG  - 1001369
LID - 10.3389/fgene.2022.1001369 [doi]
LID - 1001369
AB  - Background: Thalassemia is a common inherited hematological disease with genetic 
      disorders characterized by imbalanced synthesis of the globin chains. Due to the 
      improvement of treatment methods, patients with thalassemia can survive for a 
      long time. Therefore, it is not uncommon for patients with thalassemia suffering 
      from malignant tumors. However, there are quite few reports on thalassemia 
      patients complicated with breast cancer. Herein, we try to investigate the 
      prevalence and genetic disorders spectrum of thalassemia in patients with breast 
      cancer. Methods: Blood routing tests and serum ferritin analysis were conducted 
      in 1887 breast cancer patients treated in the department of radiation oncology 
      during 1 April 2020 and 30 March 2022. The suspected thalassemia carriers with 
      small mean corpuscular volume (MCV), mean corpuscular hemoglobin content (MCH) or 
      mean corpuscular hemoglobin concentration (MCHC) but the concentration of serum 
      ferritin within normal limits were further investigated by polymerase chain 
      reaction (PCR) and flow through hybridization gene chip to detect common 
      mutations of alpha-globin and beta-globin genes using Thalassemia Geno Array Diagnostic 
      Kit. The prevalence and genetic mutation spectrum of thalassemia among breast 
      cancer patients were analyzed. Results: Four hundred and eighty-nine suspected 
      thalassemia carriers were detected by complete blood cell counts and serum 
      ferritin analysis among 1887 breast cancer patients. One hundred and seven cases 
      (5.7%) were identified as carriers of thalassemia, of which 55 cases (51.4%) were 
      alpha-thalassemia, 50 cases (46.7%) were beta-thalassemia, and 2 cases (1.9%) were 
      co-inheritance of alpha-thalassemia and beta-thalassemia simultaneously. In 
      alpha-thalassemia, the most prevalent genotype is -(SEA)/alphaalpha; as for beta-thalassemia, 
      beta(IVS-II-654)/beta is the most common genotype. The degree of anemia is more severe 
      in beta-thalassemia than in alpha-thalassemia. Conclusion: This is the first 
      comprehensive molecular epidemiological investigation on thalassemia among breast 
      cancer patients. Our data indicated that thalassemia was not uncommon in breast 
      cancer patients. The physicians should have the knowledge to avoid misdiagnosis 
      as iron deficiency anemia.
CI  - Copyright (c) 2022 Ding, Huang, Jiang, Li, Cao and Guo.
FAU - Ding, Jingxian
AU  - Ding J
AD  - Department of Radiation Oncology, The Breast Cancer Institute, The Third Hospital 
      of Nanchang, Nanchang, China.
FAU - Huang, Zhaohui
AU  - Huang Z
AD  - Department of Radiation Oncology, The Breast Cancer Institute, The Third Hospital 
      of Nanchang, Nanchang, China.
FAU - Jiang, Xiaoliu
AU  - Jiang X
AD  - Department of Radiation Oncology, The Breast Cancer Institute, The Third Hospital 
      of Nanchang, Nanchang, China.
FAU - Li, Qingge
AU  - Li Q
AD  - Department of Radiation Oncology, The Breast Cancer Institute, The Third Hospital 
      of Nanchang, Nanchang, China.
FAU - Cao, Yali
AU  - Cao Y
AD  - Department of Breast Surgery, The Breast Cancer Institute, The Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Guo, Yonghong
AU  - Guo Y
AD  - Department of Radiation Oncology, The Fourth Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
DEP - 20221018
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC9623098
OTO - NOTNLM
OT  - anemia
OT  - breast cancer
OT  - molecular mutation spectrum
OT  - serum ferritin
OT  - thalassemia
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/05 06:01
PMCR- 2022/10/18
CRDT- 2022/11/04 02:36
PHST- 2022/07/23 00:00 [received]
PHST- 2022/10/04 00:00 [accepted]
PHST- 2022/11/04 02:36 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/05 06:01 [medline]
PHST- 2022/10/18 00:00 [pmc-release]
AID - 1001369 [pii]
AID - 10.3389/fgene.2022.1001369 [doi]
PST - epublish
SO  - Front Genet. 2022 Oct 18;13:1001369. doi: 10.3389/fgene.2022.1001369. eCollection 
      2022.